<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775502</url>
  </required_header>
  <id_info>
    <org_study_id>BIW-8962-001</org_study_id>
    <nct_id>NCT00775502</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma</brief_title>
  <official_title>Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the ability of a specially designed monoclonal antibody to destroy&#xD;
      multiple myeloma cells. This antibody is unique in its ability to promote the death of&#xD;
      multiple myeloma cells by processes known as antibody dependent cellular cytotoxicity&#xD;
      (ADCC)and complement dependent cytotoxicity (CDC). The study is designed to determine both&#xD;
      the optimal dose of the antibody to destroy multiple myeloma cells and frequency of dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIW-8962 is a monoclonal antibody which targets the GM-2 ganglioside which is expressed at&#xD;
      high levels on the surface of multiple myeloma cells. This is a Phase 1/2 study design. The&#xD;
      Phase 1 component will establish the active biologic dose (ABD) or the maximum tolerated dose&#xD;
      (MTD) as well as the appropriate dosing frequency based on the pharmacokinetics of the&#xD;
      antibody and approximately 45 subjects will be enrolled in this part of the study. The&#xD;
      initial dosing frequency will be every two weeks and the doses to be tested will range from&#xD;
      0.03 mg/kg to 10 mg/kg. Once the recommended Phase 2 dose and frequency have been established&#xD;
      in Phase 1, the efficacy of the drug will be investigated in approximately 35 subjects in&#xD;
      Phase 2.&#xD;
&#xD;
      The study did not proceed beyond the Phase 1a portion.&#xD;
&#xD;
      On 30 Nov 2010, Kyowa Hakko Kirin Pharma, Inc. (KKP) notified Investigators of the decision&#xD;
      to terminate BIW-8962-001 due to a lack of efficacy in Multiple Myeloma.&#xD;
&#xD;
      The Phase 1 Part B and the Phase 2 components of the study were not conducted. The study was&#xD;
      terminated and summarized in an abbreviated clinical study report (submitted 26 June 2012;&#xD;
      SN045). Kyowa Kirin Pharma has no current plans to pursue the use of BIW8962 in multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of efficacy in Multiple myeloma&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum M protein levels</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression or death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BIW-8962, monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIW-8962</intervention_name>
    <description>Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months</description>
    <arm_group_label>BIW-8962, monoclonal antibody</arm_group_label>
    <other_name>anti GM2 monoclonal antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory myeloma&#xD;
&#xD;
          -  M-protein in serum and/or urine by IMWG criteria.&#xD;
&#xD;
          -  Bone marrow plasma cells or plasmacytoma&#xD;
&#xD;
          -  Related organ or tissue impairment (CRAB)&#xD;
&#xD;
          -  Subjects without detectable M protein are eligible if they have an abnormal serum free&#xD;
             light chain ratio (FLC) or if they have at least 10% plasma cells in the bone marrow&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing infection&#xD;
&#xD;
          -  Cardiac disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Active liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Zonder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karmanos Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taussig Cancer Center- Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>GM-2 ganglioside</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Potelligent design</keyword>
  <keyword>Treatment of subjects who have failed previous treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

